← Back to Search

Other

Restrictive Red blood cell Transfusion for Blood Cancers (TRIST Trial)

Phase 3
Waitlist Available
Led By Jason Tay, MD FRCPC MSc
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients are aged 16-70 undergoing either an autologous or allogeneic HSCT for any hematologic malignancy
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

TRIST Trial Summary

Transfusion of red blood cells (RBCs) is important for the care of patients undergoing stem cell transplantation. Stem cell transplants are used to treat blood cancers and bone marrow disorders. This involves the use of high doses of chemotherapy and/or radiation to kill cancer cells; but this damages the marrow and blood system. Blood stem cells are transplanted by infusing into the recipient and blood counts recover over 2-3 weeks. Before bone marrow recovery, RBCs are needed to support the patient. Higher hemoglobin in these high risk patients may have benefits such as better energy and organ function. However, research in other areas of medicine suggests that a higher red cell count may be dangerous. Taken together, it is unclear whether having a lower or higher red cell count is better for patients having a blood stem cell transplant. The investigators plan to study this by randomly assigning patients having a transplant to be transfused with RBCs either at a higher or lower hemoglobin level. In this way, the investigators will be able to accurately find out if there are any benefits or harms in having a lower or higher red cell count during the recovery period after blood stem cell transplantation.

Eligible Conditions
  • Blood Cancers

TRIST Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

TRIST Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Quality of Life (QOL)/Function based on the FACT-BMT scale
Secondary outcome measures
Acute Graft Versus Host Disease
Bleeding
Economic Evaluation/Quality of Life
+6 more

TRIST Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Restrictive Red blood cell TransfusionExperimental Treatment1 Intervention
Transfusion Trigger of 70g/L with an aim to maintain Hemoglobin between 80-90g/L
Group II: Liberal Red blood Cell TransfusionActive Control1 Intervention
Transfusion Trigger of 90g/L with an aim to maintain Hemoglobin between 100-110g/L

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
564 Previous Clinical Trials
2,787,567 Total Patients Enrolled
Canadian Blood ServicesOTHER
20 Previous Clinical Trials
20,339 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,354 Previous Clinical Trials
26,459,906 Total Patients Enrolled
~21 spots leftby Jun 2025